Joe Schultz

@ajw02360 I highly doubt there’s a run-up of stock price and then they issue this huge dilution to lower the stock price down rather than let the run-up happen. They do have sales for compassionate care that brings in a lot of revenue.

@BrnAgainHuman Because the company has no money and relies on dilution for funding. You are a shareholder of $NWBO and are unaware the company funds itself by issuing more shares? You truly are next-level stupid.

$NWBO and back down she goes. Company diluting?? Probably.

@jaygreco194737 Why on earth would Linda want to knock the price down? I see how citadel would. I see how short shorts would I don’t see why Linda would.

$NWBO Linda is that you knocking the price down or is it something else?

@DontheConDrumpf Please elaborate. Is this one of the market makers that’s part of the spoofing case?

$nwbo actual arrests.

@d_stock07734 This was all about clinical trials if I listened properly and Northwest biotherapeutics is awaiting approval for DC VAXL because it published the results of its clinical trial in JAMA. So explain why this video is irrelevant now.

$NWBO Do we love the word 'platform'? prnewswire.com/news-releases/…

@juswilpwr @BioNorthwest702 Approval = $5-$20 by historical comparisons = generational wealth.

I challenge all the $nwbo pumpers to show me a bio stock that created generational wealth upon approval some even go down in value most go up 5-20% and #nwbo only has one vaccine pending in Europe. Even fda approval can’t take it over 20-30% with 1.7 BILLION shares outstanding

@BioNorthwest702 @mabbpah @PK_Fund What is your goal here? You clearly don’t like this company you take its name for the Twitter feed. There’s a lot of companies out there if you don’t like this one pick another one. The goal of biotech is the company succeed for healthcare treatments.

@mabbpah @PK_Fund Danish dildo and Hoffscam some of the biggest pumpers promoting their own agenda and getting into anyone’s face that disagreed with management or cronies (probably hired by $nwbo) and the furthest off. What jokers #nwbo be wary before investing a cent into $nwbo

$NWBO Just his speculation. Not financial Advice

@CreepyBrent1 @justinkeister5 $10-$25 B valuation upon approval is $4-$10 a share

@justinkeister5 Y’all and your $nwbo conspiracy theories. Dont you realize that #nwbo will have 2.7 Billion shares outstanding. That’s more than $MRK who has 53 drugs approved worldwide. NWBO cant even get 1 approved in Europe. Sounds like the $.20 value is correct

I hope the MMs have to trade 3 billion shares on approval day to keep the price under $1. I hope approval day +1 the compay is sold for $10B+.

@DWpaMont @GoneGoodguy Can you give more details, please? Are you saying they’re applying for agnostic tumor approval? That’s a huge gamble and would explain this giant delay, but it also makes the upside probably about 100 X over what it was before.

Now we know what's holding up #NWBO's DCVax-L approval is!!! "In summary, the procurement license acts as a critical prerequisite for the quality compliance of the ATMP, and its absence or delay can cause significant pauses or rejection of the MAA". investorshub.advfn.com/boards/read_ms…

@BioNorthwest702 Why do you spend so much time and energy posting negative news? Don’t you have better things to do with your time?

Why isn’t Hoffscam posting anymore about $nwbo ? Only when legal stuff comes out. It’s almost as if #nwbo paid him to start posting knowing they were going into this lawsuit. Oh wait a second ….

@d_stock07734 Is this northwest or is this a different company?

$NWBO April marks the primary completion of a DC1 vaccine trial (NCT05378464) conducted at Moffitt Cancer Center. The trial is about the following combination: DC1 vaccine + Pepinemab(SEMA4D inhibitor) + Trastuzumab (HER2 inhibitor) + IL-15 Expanded HER2 specific CD4 Th1 cell + IL-7 Expanded HER2 specific CD4 Th1 cell It is interesting IL-7 was used to expand HER2 CD4 Th1 cell. Is IL-7 about CYT107? I suppose the results should be blockbuster given that the combination of DC1 vaccine with Pepinemab(SEMA4D inhibitor) and Trastuzumab (HER2 inhibitor) can significantly shrink tumors in animal model. Of course, Merck must conduct a trial on the combination of SEMA4D inhibitor with Keytruda. I suppose Merck might acquire Vaccinex, which should happen before the publication of the results on the trial NCT05378464. Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine & Pepinemab /​Trastuzumab in Patients w/​ Metastatic HER2+ Breast Cancer clinicaltrials.gov/study/NCT05378… Pepinemab in Combination With Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (KEYNOTE-B84) clinicaltrials.gov/study/NCT04815… Clinical Collaboration Partner: Merck vaccinex.com/partners/ Potentiating dendritic cell immunotherapy by interrupting the Semaphorin 4D-induced immune-suppressive barrier cell.com/cell-reports/f… Combination therapy with semaphorin-4D blockade (SEMA4D) and DC1 therapy patents.google.com/patent/EP39864…

@Bigsky716 Yesterday someone posted that they’re still responding to RFI’s. If they are still responding to RFI’s, they do not see how app approval is happening anytime soon you can happen in May. But unless it’s like the last thing, they need to know which it very well may be.

@irpcp61598779 If all the new shares that were approved or issued, that’s 1/3 dilution. Dilution is not a major concern approval is Why it’s taking five times longer that is the mystery England Brexit really created headaches for everyone and has slowed everything down

$NWBO investor with 3.1M shares here. It is concerning that the MAA is taking five times longer than expected while the price drops and dilution continues. Is management doing enough to reassure us?

@CscottLawyer @jstrattman @Smyley4evr1 @LeahDavis199340 How do you get the second CHM meeting? Where was this determined? How do we know any of this information? Why 91 days? Is this ironclad? I know the UK is really messed up because of Brexit so how do you have this information?

@jstrattman @Smyley4evr1 @LeahDavis199340 $NWBO I think MHRA issued a 2nd RFI to NWBO based on two inferences. 1. It has been 91 days since the 2nd CHM meeting. That is too long for straight up approval. 2. NWBO would not fail to disclose a CHM Letter. They would be sued under SEC Rule 10(b)(5).

$NWBO The thesis here is simple. If management had zero confidence in approval, they wouldn’t be expanding facilities and hiring aggressively. Capital moves signal expectations.

@sharpie510 @DCVaxDefender Another two months? I will see how a delay helps them get this thing to market can still showcase it. show me the money.

@DCVaxDefender It might be to allow MHRA, NICE, and $NWBO to showcase #DCVax-L with the Medicines for Human Use (Clinical Trials) (Amendment) Regulations 2025 which becomes law on April 28, 2026. A coordinated PR from all 3 would shut down the FUD and provide sustained share price support. 🤞

The third and likely FINAL debate on the Rare Cancers Bill is happening tomorrow, Friday, February 27, 2026 at 10:00 AM (GMT). It is expected to pass unopposed. 🙏 This paves the way for a NICE meeting with $NWBO on #DCVax-L pricing, perhaps on March 4, 2026. 🤞

@d_stock07734 @patrickwalsh14 I’m pretty sure if they want it they can buy it today for not too much money

@patrickwalsh14 Ten years ago, Merck could have acquired $NWBO with a big check. Today, Merck’s pocket may not be deep enough to buy $NWBO. As shown in the figure, by developing different maturation cocktails, $NWBO can have tolerogenic DC vaccine to treat autoimmune diseases.

$NWBO Has Merck sorted out how to get T-cells show up in tumor site in a massive and sustainable way? Seems to me almost all Merck's 20 novel mechanisms in oncology work only under the condition: Getting plenty T-cells showing up in tumor site first. Seems to me antigen-presenting cells (Dendritic cells) in the figure play an essential role in activating anti-tumor immune response. Has Merck been collecting the puzzles related to stimulatory and inhibitory factors related to anti-tumor immune response? I am curious if Merck gets the check ready before making the decision for the split. Girding against Keytruda cliff, Merck splits oncology into standalone business unit fiercepharma.com/pharma/girding… How Merck scientists are driving next-generation cancer research merck.com/stories/how-me…

@CscottLawyer @SnackBioTech @PJC3251 Where are you getting this information? Is this real or speculative?

@SnackBioTech @PJC3251 $NWBO. The clock ran for 53 days through 11/20/25 when OHEAG considered DCVax-L, or through 11/27-28/25 when CHM considered DCVax-L. NWBO was at Day 143 on 11/28/25. I am confident that the CHM did not issue a CHM Letter to NWBO. Such a letter would stop the clock for 28 days

$NWBO missed all timelines for recent review again. The MAA is stalled because $NWBO cannot provide the answers to questions being asked. There is an end point here. I said years ago that $NWBO has interesting data, but they need a new phase 3 trial. Explains the delay and the share expansion.

@banksy15490887 A lot of people were speculating today there would be positive news and there’s not so it’s just the share price pulling him back, but the volume is relatively low and the pullback is relatively low so overall the market is fairly optimistic

What the f***k is it now! $nwbo

@Mtnjack68 The volume is very very low today and it’s really not down that far just a little bit so these reports of it crashing are being highly over blown.

Damn, $NWBO this can’t be good. But I thought the Cult said this is it? BTW this is one of two accounts I have with this shit company. Come pumpers, get this to $.39 and I’m out.

@neilmck37597308 That isn’t an accurate statement now is it. You posted this over an hour ago and it’s not down anymore and under 1 million shares have traded so it’s down a smidge on very low volume.

$nwbo as expected SP dropping like an 50lb anchor, grr. LP time to man up!